{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T06:27:54Z","timestamp":1789021674084,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T00:00:00Z","timestamp":1613347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T00:00:00Z","timestamp":1613347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>To date, two randomized, controlled studies support the use of candesartan for migraine prophylaxis but with limited external validity. We aim to evaluate the effectiveness and tolerability of candesartan in clinical practice and to explore predictors of patient response. Retrospective cohort study including all patients with migraine who received candesartan between April 2008-February 2019. The primary endpoint was the number of monthly headache days during weeks 8\u201312 of treatment compared to baseline. Additionally, we evaluated the frequency during weeks 20\u201324. We analysed the percentage of patients with 50% and 75% response rates and the retention rates after three and 6\u00a0months of treatment. 120\/4121 patients were eligible, aged 45.9 [11.5]; 100 (83.3%) female. Eighty-four patients (70%) had chronic migraine and 53 (42.7%) had medication-overuse headache. The median number of prior prophylactics was 3 (Inter-quartile range 2\u20135). At baseline, patients had 20.5\u2009\u00b1\u20098.5 headache days per month, decreasing 4.3\u2009\u00b1\u20098.4\u00a0days by 3\u00a0months (weeks 12\u201316) and by 4.7\u2009\u00b1\u20098.7\u00a0days by 6\u00a0months (paired Student\u2019s t-test,<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). The percentage of patients with a 50% response was 32.5% at 3\u00a0months and 31.7% at 6\u00a0months, while the retention rate was 85.0% and 58.3%. The number of prior treatments (Odds ratio 0.79, 95% CI 0.64\u20130.97) and the presence of daily headache (Odds ratio 0.39, 95% CI 0.16\u20130.97) were associated with a lower probability of response. Candesartan showed beneficial effects in the preventive treatment of migraine in clinical practice, including patients with chronic migraine, medication-overuse headache and resistance to prior prophylactics.<\/jats:p>","DOI":"10.1038\/s41598-021-83508-2","type":"journal-article","created":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T14:31:41Z","timestamp":1613572301000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Real world effectiveness and tolerability of candesartan in the treatment of migraine: a retrospective cohort study"],"prefix":"10.1038","volume":"11","author":[{"given":"Carmen","family":"S\u00e1nchez-Rodr\u00edguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"Sierra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"Planchuelo-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Mart\u00ednez-P\u00edas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngel L.","family":"Guerrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Garc\u00eda-Azor\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,15]]},"reference":[{"issue":"20","key":"83508_CR1","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/0024-3205(92)90627-2","volume":"51","author":"K Mizuno","year":"1992","unstructured":"Mizuno, K. et al. Hypotensive activity of TCV-116, a newly developed angiontensin II receptor antagonist, in spontaneously hypertensive rats. Life Sci. 51(20), 183\u2013187 (1992).","journal-title":"Life Sci."},{"issue":"4","key":"83508_CR2","first-page":"684","volume":"15","author":"T Ogihara","year":"1993","unstructured":"Ogihara, T., Higashimori, K., Masuo, K. & Mikami, H. Pilot study of a new angiontensin II receptor antagonist, TCV-116: effects of a single dose on blood pressure in patients with essential hypertension. Clin. Ther. 15(4), 684\u2013191 (1993).","journal-title":"Clin. Ther."},{"key":"83508_CR3","first-page":"749","volume":"7","author":"R Cernes","year":"2011","unstructured":"Cernes, R., Mashavi, M. & Zimlichman, R. Differential clinical profile of candesartan compared to other angiotensin receptor blockers. Vasc. Health Risk Manag. 7, 749\u2013759 (2011).","journal-title":"Vasc. Health Risk Manag."},{"issue":"1","key":"83508_CR4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/jama.289.1.65","volume":"289","author":"E Trovnik","year":"2003","unstructured":"Trovnik, E., Stovner, L. J., Helde, G., Sand, T. & Bovim, G. Prophylactic treatment of migraine with an angiotensin II receptor blocker. A randomized controlled trial. JAMA 289(1), 65\u201369 (2003).","journal-title":"JAMA"},{"issue":"7","key":"83508_CR5","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1177\/0333102413515348","volume":"34","author":"LJ Stovner","year":"2014","unstructured":"Stovner, L. J. et al. A comparative study of candesartan versus propranolol for migraine prophylaxis: a randomised, triple-blind, placebo-controlled, double cross-over study. Cephalalgia 34(7), 523\u2013532 (2014).","journal-title":"Cephalalgia"},{"issue":"6","key":"83508_CR6","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1291\/hypres.27.441","volume":"27","author":"K Owada","year":"2004","unstructured":"Owada, K. Efficacy of Candesartan in the treatment of migraine in hypertensive patients. Hypertens. Res. 27(6), 441\u2013446 (2004).","journal-title":"Hypertens. Res."},{"key":"83508_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-09989-9","author":"R Messina","year":"2020","unstructured":"Messina, R., Lastarria Perez, C. P., Filippi, M. & Goadsby, P. J. Candesartan in migraine prevention: results from a retrospective real-world study. J Neurol. https:\/\/doi.org\/10.1007\/s00415-020-09989-9 (2020).","journal-title":"J Neurol."},{"issue":"9","key":"83508_CR8","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1111\/j.1468-1331.2009.02748.x","volume":"16","author":"S Evers","year":"2009","unstructured":"Evers, S. et al. EFNS guideline on the drug treatment of migraine\u2014revised report of an EFNS task force. Eur J Neurol 16(9), 968\u2013981 (2009).","journal-title":"Eur J Neurol"},{"issue":"17","key":"83508_CR9","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1212\/WNL.0b013e3182535d20","volume":"78","author":"SD Silberstein","year":"2012","unstructured":"Silberstein, S. D. et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the quality standards subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 78(17), 1337\u20131345 (2012).","journal-title":"Neurology"},{"issue":"1","key":"83508_CR10","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1007\/s10194-011-0402-9","volume":"13","author":"L Bendtsen","year":"2012","unstructured":"Bendtsen, L. et al. Reference programme: diagnosis and treatment of headache disorders and facial pain. J. Headache Pain 13(1), S1\u2013S29 (2012).","journal-title":"J. Headache Pain"},{"issue":"suppl 2","key":"83508_CR11","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1007\/s10194-012-0437-6","volume":"13","author":"P Sarchielli","year":"2012","unstructured":"Sarchielli, P. et al. Italian Guidelines for primary headaches: 2012 revised version. J. Headache Pain 13(suppl 2), S31\u2013S70 (2012).","journal-title":"J. Headache Pain"},{"issue":"2 Suppl 2","key":"83508_CR12","first-page":"S1","volume":"39","author":"T Pringsheim","year":"2012","unstructured":"Pringsheim, T. et al. Canadian Headache Society guideline for migraine prophylaxis. Can. J. Neurol. Sci. 39(2 Suppl 2), S1\u2013S59 (2012).","journal-title":"Can. J. Neurol. Sci."},{"key":"83508_CR13","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1129-2377-15-2","volume":"15","author":"M Lanteri-Minet","year":"2014","unstructured":"Lanteri-Minet, M., Valade, D., Geraud, G., Lucas, C. & Donnet, A. Revised French guidelines for the diagnosis and management of migraine in adults and children. J. Headache Pain 15, 2 (2014).","journal-title":"J. Headache Pain"},{"key":"83508_CR14","unstructured":"Ezpeleta, D. & Pozo-Rosich, P. Gu\u00eda oficial de pr\u00e1ctica cl\u00ednica en cefaleas. Editorial Luz\u00e1n 5, Madrid, Spain (2015). ISBN: 978-84-15198-99-4."},{"key":"83508_CR15","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s10194-019-1060-6","volume":"20","author":"E Kouremenos","year":"2019","unstructured":"Kouremenos, E. et al. Consensus of the hellenic headache society on the diagnosis and treatment of migraine. J. Headache Pain 20, 113 (2019).","journal-title":"J. Headache Pain"},{"issue":"1","key":"83508_CR16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s10194-019-0971-6","volume":"20","author":"D Garc\u00eda-Azor\u00edn","year":"2019","unstructured":"Garc\u00eda-Azor\u00edn, D., Santos-Lasaosa, S., Gago-Veiga, A. B., Viguera Romero, J. & Guerrero-Peral, A. L. Real world preventative drug management of migraine among Spanish neurologists. J. Headache Pain 20(1), 19 (2019).","journal-title":"J. Headache Pain"},{"issue":"21","key":"83508_CR17","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1001\/jama.2017.1680","volume":"317","author":"Prevention of Migraine","year":"2017","unstructured":"Prevention of Migraine. JAMA 317(21), 2230\u20132231 (2017).","journal-title":"JAMA"},{"issue":"10","key":"83508_CR18","doi-asserted-by":"publisher","first-page":"e296","DOI":"10.1371\/journal.pmed.0040296","volume":"4","author":"E Von Elm","year":"2007","unstructured":"Von Elm, E. et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med 4(10), e296 (2007).","journal-title":"PLoS Med"},{"key":"83508_CR19","unstructured":"Good clinical practice: consolidate guideline. In Proceedings of the International Conference on Harmonisation of Technical Requirements for Registrations of Pharmaceuticals for Human Use, Geneva. International Conference on Harmonisation (1996)."},{"issue":"Suppl 1","key":"83508_CR20","first-page":"9","volume":"24","author":"Headache Classification Subcommittee of the International Headache Society","year":"2004","unstructured":"Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders: 2nd edition. Cephalalgia 24(Suppl 1), 9\u2013160 (2004).","journal-title":"Cephalalgia"},{"key":"83508_CR21","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1177\/0333102413485658","volume":"9","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2013","unstructured":"Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition (beta version). Cephalalgia 9, 629\u2013808 (2013).","journal-title":"Cephalalgia"},{"issue":"1","key":"83508_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","volume":"38","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2018","unstructured":"Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia 38(1), 1\u2013211 (2018).","journal-title":"Cephalalgia"},{"issue":"5","key":"83508_CR23","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1177\/0333102418758283","volume":"38","author":"C Tassorelli","year":"2018","unstructured":"Tassorelli, C. et al. Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults. Cephalalgia 38(5), 815\u2013832 (2018).","journal-title":"Cephalalgia"},{"issue":"1","key":"83508_CR24","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach for multiple testing. J. R. Stat. Soc. Ser. B 57(1), 289\u2013300 (1995).","journal-title":"J. R. Stat. Soc. Ser. B"},{"issue":"2","key":"83508_CR25","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1526-4610.2007.00914.x","volume":"48","author":"NT Mathew","year":"2008","unstructured":"Mathew, N. T., Kailasam, J. & Meadors, L. Predictors of response to botulinum toxin type A (BoNTA) in chronic daily headache. Headache 48(2), 194\u2013200 (2008).","journal-title":"Headache"},{"issue":"2","key":"83508_CR26","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/ene.13523","volume":"25","author":"C Dom\u00ednguez","year":"2018","unstructured":"Dom\u00ednguez, C. et al. OnabotulinumtoxinA in chronic migraine: predictors of response. A prospective multicentre descriptive study. Eur. J. Neurol. 25(2), 411\u2013416 (2018).","journal-title":"Eur. J. Neurol."},{"issue":"2","key":"83508_CR27","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S0895-7061(00)01240-1","volume":"14","author":"A Zanchetti","year":"2001","unstructured":"Zanchetti, A. & Omboni, S. Comparison of candesartan versus enalapril in essential hypertension. Am. J. Hypertens. 14(2), 129\u2013134 (2001).","journal-title":"Am. J. Hypertens."},{"issue":"6","key":"83508_CR28","doi-asserted-by":"publisher","first-page":"407","DOI":"10.2165\/00044011-200727060-00004","volume":"27","author":"JL Palma-Gamiz","year":"2007","unstructured":"Palma-Gamiz, J. L. et al. A multicentre, 12-week study of imidapril and candesartan cilexetil in patients with mild to moderate hypertension using ambulatory blood pressure monitoring. Clin. Drug Investig. 27(6), 407\u2013417 (2007).","journal-title":"Clin. Drug Investig."},{"issue":"1","key":"83508_CR29","first-page":"S139","volume":"24","author":"E Trovnik","year":"2006","unstructured":"Trovnik, E., Stovner, L. J., Schrader, H. & Bovim, G. Involvement of the Renin-Angiotensin system in migraine. J. Hypertens. Suppl. 24(1), S139\u2013S143 (2006).","journal-title":"J. Hypertens. Suppl."},{"issue":"9","key":"83508_CR30","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1586\/14737175.2014.946408","volume":"14","author":"P Ripa","year":"2014","unstructured":"Ripa, P., Ornello, R., Pistoia, F., Carloei, A. & Sacco, S. The renin-angiotensin system: a posible contributor to migraine pathogenesis and prophylaxis. Expert Rev. Neurother. 14(9), 1043\u20131055 (2014).","journal-title":"Expert Rev. Neurother."},{"issue":"2","key":"83508_CR31","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1345\/aph.1M312","volume":"44","author":"BJ Gales","year":"2010","unstructured":"Gales, B. J., Bailey, E. K., Reed, A. N. & Gales, M. A. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for the prevention of migraines. Ann. Pharmacother. 44(2), 360\u2013366 (2010).","journal-title":"Ann. Pharmacother."},{"issue":"11","key":"83508_CR32","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s11916-019-0823-8","volume":"23","author":"T Dorosch","year":"2019","unstructured":"Dorosch, T., Ganzer, C. A., Lin, M. & Seifan, A. Efficacy of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the preventative treatment of episodic migraine in adults. Curr. Pain Headache Rep. 23(11), 85 (2019).","journal-title":"Curr. Pain Headache Rep."},{"issue":"8","key":"83508_CR33","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/S0002-9343(02)01100-2","volume":"112","author":"M Etminan","year":"2002","unstructured":"Etminan, M., Levine, M. A. H., Tomlinson, G. & Rochon, P. A. Efficacy of angiotensin II receptor antagonists in preventing headache: a systematic overview and meta-analysis. Am. J. Med. 112(8), 642\u2013646 (2002).","journal-title":"Am. J. Med."},{"issue":"9","key":"83508_CR34","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1111\/j.1468-2982.2008.01825.x","volume":"29","author":"HC Diener","year":"2009","unstructured":"Diener, H. C. et al. Telmisartan in migraine prophylaxis: a randomized, placebo-controlled trial. Cephalalgia 29(9), 921\u2013927 (2009).","journal-title":"Cephalalgia"},{"issue":"5","key":"83508_CR35","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s10072-017-2854-4","volume":"38","author":"K Ikeda","year":"2017","unstructured":"Ikeda, K. et al. Treatment with telmisartan, a long-acting angiotensin II receptor blocker, prevents migraine attacks in Japanese non-responders to lomerizine. Neurol. Sci. 38(5), 827\u2013831 (2017).","journal-title":"Neurol. Sci."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-83508-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-83508-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-83508-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T09:41:40Z","timestamp":1724492500000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-83508-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,15]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["83508"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-83508-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,15]]},"assertion":[{"value":"2 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3846"}}